Reuters logo
BRIEF-Coherus announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint
March 2, 2017 / 2:33 PM / 9 months ago

BRIEF-Coherus announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint

March 2 (Reuters) - Coherus Biosciences Inc

* Coherus announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint

* Coherus Biosciences - results gives confidence co can similarly complete future PK studies with modified formulations, exepcted to commence later in 2017

* Coherus Biosciences - study met criteria for clinical PK similarity on all prospectively defined PK endpoints Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below